• A F Shorr, L K Moores, W J Edenfield, R J Christie, and T M Fitzpatrick.
• Division of Pulmonary & Critical Care Medicine, Walter Reed Army Medical Center, Washington, DC 20307, USA. CPT_Andrew_Shorr@WRAMC1.AMEDD.ARMY.MIL
• Chest. 1999 Oct 1; 116 (4): 1012-8.

BackgroundSurvival rates from mechanical ventilation (MV) in allogeneic bone marrow transplantation are poor, but little is known about the need for and outcomes from MV in patients who undergo autologous hematopoietic stem cell transplantation (AHSCT).Study ObjectiveTo determine the frequency of and risk factors for the use of MV in recipients of AHSCT and to identify predictors of survival in mechanically ventilated AHSCT patients.DesignRetrospective, cohort analysisSettingTertiary-care, university-affiliated medical center.PatientsOne hundred fifty-nine consecutive patients who underwent AHSCT.InterventionsPatient surveillance and data collection.Measurements And ResultsThe primary outcome measure was the need for MV, and the secondary end point was survival after MV. Of 159 patients, 17 required MV (10. 7%). Three variables were associated with the need for MV: increasing age, use of total body irradiation in the conditioning regimen, and treatment with amphotericin B. As a screening test to predict the need for MV, no risk factor had a sensitivity or specificity > 82%. Three of the 17 mechanically ventilated patients (17.6%) survived to discharge. Only the mean APACHE (acute physiology and chronic health evaluation) II score separated survivors from nonsurvivors (21.7 vs 31.4; p = 0.029). Both the duration of MV and the length of stay in the ICU were similar in survivors and nonsurvivors.ConclusionsWe conclude that MV is infrequently needed following AHSCT. Although survival after MV in these patients is limited, clinical variables do not reliably allow clinicians to prospectively identify patients destined to die.

22 keywords...

hide…